Immunic (IMUX)
(Delayed Data from NSDQ)
$1.21 USD
-0.06 (-4.72%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $1.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 101 - 120 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838 Multiple Sclerosis Clinical Program Defined; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Immunic Advances to Phase 3 in RRMS and Explores Oppy in Progressive MS
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
FDA Cleared RRMS Phase 3s and PMS Phase 2, Dosing Starts in H2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-935 Shows Encouraging SAD PK PD Data in Healthys. MAD Data in 2H2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Sclerosis Trial Starting; COVID-19 Plan Halted; Lowering PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q1; Pipeline Progress; Initiation of RRMS Ph3 Anticipated in H2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Pullback Is Temporary, Don''t Lose Sight of Key Value Drivers
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Sub-trial Data Support 30mg Dose Selection for IMMU-838/RRMS Pivotal Phase 3s
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Multiple Sclerosis Studies Completed, Phase 3 to Initiate in 2H21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights PSC Unmet Need & Potential Pivotal Study Endpoints
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Piecing Together The Opportunity in PSC; KOL Call on Thursday, April 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department